RPG Life Sciences Ltd

The company's financial performance shows signs of stress despite moderate sales growth. While Trailing Twelve Months (TTM) sales grew by 8%, this has not translated into profitability. Compounded profit growth for the TTM period is negative at -5%, and the annual profit for Mar 2026 also shows a 5% decline. This indicates a significant issue with converting revenue into profit. The Operating Profit Margin (OPM) has also contracted from 24% in Mar 2025 to 21% in Mar 2026. Quarterly performance is volatile; for instance, YOY profit growth was -18.32% in Dec 2025 but swung to 33.70% in Mar 2026, highlighting earnings inconsistency. The core net profit margin, based on annual profit excluding exceptional items, also declined from 18.1% in Mar 2025 to 15.8% in Mar 2026, questioning the strength of core operations. | Metric | Mar 2025 | Mar 2026 | TTM | |---|---|---|---| | Sales Growth (%) | | 8.28% | 8% | | Profit Growth (%) | | -5% | -5% | | OPM (%) | 24% | 21% | - | | Core NPM (Annual) (%) | 18.1% | 15.8% | - |

Management has demonstrated strong capabilities in generating returns from its capital base. The company reports an excellent Return on Capital Employed (ROCE) of 26% for Mar 2026 and a Return on Equity (ROE) of 20.3%, indicating productive use of both debt and equity capital. However, recent trends in working capital management are concerning. The Cash Conversion Cycle (CCC) has deteriorated significantly, increasing from 72 days in Mar 2025 to 99 days in Mar 2026. This is driven by an increase in both Debtor Days (from 48 to 60) and Inventory Days (from 159 to 179), suggesting inefficiencies in collecting receivables and managing stock. Additionally, the asset turnover ratio has seen a slight decline from 0.99 to 0.89, indicating that assets are being converted into revenue less effectively than in the previous year. | Metric | Mar 2025 | Mar 2026 | |---|---|---| | ROCE (%) | - | 26% | | ROE (%) | 22.2% | 20.3% | | Cash Conversion Cycle (Days) | 72 | 99 | | Asset Turnover Ratio | 0.99 | 0.89 |

The company's financial health is exceptionally strong. The balance sheet is robust, with a negligible debt-to-equity ratio of 0.03 as of Mar 2026. The company was virtually debt-free in Mar 2025 and has only taken on a small amount of borrowing (₹20 Cr) in the latest year, which is insignificant relative to its equity base of ₹605 Cr. This low leverage translates into a very high Interest Coverage Ratio of 147 times, meaning operating profits can comfortably cover interest obligations many times over. The company also maintains a healthy Dividend Payout ratio of 34% in Mar 2026. The Enterprise Value is primarily driven by its market capitalization rather than debt, underscoring the company's solid financial foundation and minimal financial risk. | Metric | Mar 2025 | Mar 2026 | |---|---|---| | Borrowings (Cr) | 0 | 20 | | Debt/Equity Ratio | 0.00 | 0.03 | | Interest Coverage Ratio | 160 | 147 | | Dividend Payout (%) | 0% | 34% |

The shareholding structure signals strong confidence from both promoters and institutional investors. Promoter holding is high and stable, standing at 72.95% in Mar 2026. This figure has remained consistently above 72% for several years. More notably, there has been a sharp and sustained increase in Domestic Institutional Investor (DII) holding. DIIs have increased their stake from a mere 0.11% in Mar 2023 to 7.45% in Mar 2026, demonstrating growing confidence from sophisticated domestic investors. While Foreign Institutional Investor (FII) holding has been more volatile, it has also seen a general upward trend over the long term. This strong ownership profile, characterized by high promoter conviction and rising institutional participation, is a significant strength. | Shareholding (%) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |---|---|---|---|---|---| | Promoters | 72.07% | 72.82% | 72.82% | 72.95% | 72.95% | | FIIs | 0.12% | 0.38% | 0.90% | 1.46% | 0.87% | | DIIs | 0.01% | 0.11% | 2.16% | 6.14% | 7.45% |

A significant red flag is the high volatility and magnitude of 'Exceptional items' in its profit and loss statements. These items obscure the true underlying performance of the core business. In the Mar 2025 quarter, the reported Net Profit of ₹117 Cr was heavily inflated by a positive exceptional item of ₹95.6 Cr. In contrast, the Dec 2025 quarter included a negative exceptional item of ₹6.4 Cr. This inconsistency makes year-on-year and quarter-on-quarter comparisons of reported profitability unreliable. The sheer size and frequency of these adjustments create uncertainty and reduce the overall quality and predictability of earnings. | Metric (₹ Cr) | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |---|---|---|---|---| | Net Profit | 117.35 | 36.85 | 22.13 | 29.90 | | Exceptional items AT | 95.60 | 8.36 | -6.40 | 0.82 | | Profit excl Excep | 21.75 | 28.49 | 28.53 | 29.08 |

Operational risks are increasing, reflected in deteriorating efficiency and profitability metrics. The Cash Conversion Cycle has worsened from 72 days to 99 days in a single year, indicating growing pressure on working capital. This is a result of both slower receivables collection (Debtor Days up from 48 to 60) and longer inventory holding periods (Inventory Days up from 159 to 179). Simultaneously, core profitability is under pressure, with the annual Operating Profit Margin (OPM) contracting from 24% to 21%. This combination of declining margins and weakening working capital management signals rising operational challenges. | Metric | Mar 2025 | Mar 2026 | Trend | |---|---|---|---| | Cash Conversion Cycle (Days) | 72 | 99 | Deteriorating | | Operating Profit Margin (%) | 24% | 21% | Declining | | Asset Turnover Ratio | 0.99 | 0.89 | Declining |